ArticleThe Journal of biological chemistry2010
CD300 heterocomplexes, a new and family-restricted mechanism for myeloid cell signaling regulation.
Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- CD300a: An Innate Immune Checkpoint Shaping Tumor Immunity and Therapeutic Opportunity.Cancers · 2025Review
- Evolutionary analysis of CD300A and CD300C paired receptors in primates.Frontiers in immunology · 2025Article
- Identification of hub genes and biological mechanisms underlying the pathogenesis of asthenozoospermia and chronic epididymitis.Frontiers in genetics · 2023Article
- CD300a Receptor Blocking Enhances Early Clearance ofFrontiers in immunology · 2021Article
- CD300f immunoreceptor is associated with major depressive disorder and decreased microglial metabolic fitness.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis.Scientific reports · 2017Article
- A key requirement for CD300f in innate immune responses of eosinophils in colitis.Mucosal immunology · 2017Article
- Article
- Article
- Enhanced efferocytosis by dendritic cells underlies memory T-cell expansion and susceptibility to autoimmune disease in CD300f-deficient mice.Cell death and differentiation · 2016Article
- Identification and Characterization of CD300H, a New Member of the Human CD300 Immunoreceptor Family.The Journal of biological chemistry · 2015Article
- CD300f immunoreceptor contributes to peripheral nerve regeneration by the modulation of macrophage inflammatory phenotype.Journal of neuroinflammation · 2015Article
- CD300f associates with IL-4 receptor α and amplifies IL-4-induced immune cell responses.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Role of phosphatidylserine receptors in enveloped virus infection.Journal of virology · 2014Article
- CMRF35-like molecule 1 (CLM-1) regulates eosinophil homeostasis by suppressing cellular chemotaxis.Mucosal immunology · 2014Article
- Human CD300C delivers an Fc receptor-γ-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition.The Journal of biological chemistry · 2013Article
- Review
- CD300c is an activating receptor expressed on human monocytes.Journal of innate immunity · 2013Article
- Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury.Brain pathology (Zurich, Switzerland) · 2012Article
- Cloning and characterization of CD300d, a novel member of the human CD300 family of immune receptors.The Journal of biological chemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CD300 family of myeloid immunoglobulin receptors includes activating (CD300b, CD300e) and inhibitory members (CD300a, CD300f), as well as molecules of uncertain function presenting a negative charge within their transmembrane domain (CD300c, CD300d). In this paper, we establish that CD300c is a functional immune receptor able to deliver activating signals upon ligation in RBL-2H3 mast cells. CD300c signaling is partially mediated by a direct association with the immune receptor tyrosine-based activation motif-bearing adaptor FcεRγ. The existence of complementary transmembrane-charged residues in certain CD300 receptors suggested the formation of heterodimers within this family. Indeed, we proved the interaction between CD300b and CD300c in transfected COS-7 cells and demonstrated that it has important functional consequences. Unexpectedly, dimmer formation was dependent on the immunoglobulin domains rather than the charged transmembrane residues. Concordantly, all CD300 members were found to interact with each other, even with themselves, forming both homo- and heterodimers. We found that the combination of CD300 receptors in a complex differentially modulates the signaling outcome, strongly suggesting a new mechanism by which CD300 complexes could regulate the activation of myeloid cells upon interaction with their natural ligands.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.